Xvivo demonstrated once again that it is back on track and generating positive free cash flow. While sales slightly beat our forecast/consensus, the gross margin was 4%-points below our forecast, holding back a beat on EBIT. Still, the overall numbers are positive, and with the US heart study data presented yesterday, we expect the share price momentum to sustain and expect the share to react positively by 3-5%.
LÄS MER
